Xencor, Inc. (XNCR) Q3 2025 10-Q Summary
Business Context and Reporting Period
Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics for cancer and autoimmune diseases. This report covers the quarterly period ended September 30, 2025. The company operates as a single reportable segment and relies on collaboration revenues, milestone payments, and royalties, as it has no internally developed products approved for commercial sale.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $20,999 | $17,796 | $97,339 | $57,700 |
| Net Loss (Attributable to Xencor) | $(6,027) | $(46,288) | $(85,270) | $(187,065) |
| Operating Loss | $(47,519) | $(55,197) | $(123,874) | $(165,230) |
| R&D Expenses | $54,367 | $58,226 | $174,610 | $176,630 |
| Cash & Cash Equivalents | $28,291 | $40,875 | Balance Sheet: $28,291 (Sep 30, 2025) | |
| Marketable Securities (Debt & Equity) | Total: $605,651 (Debt) + $84,260 (Equity) = $689,911 | |||
| Liabilities (Royalty Sales) | Total: $133,138 (Current: $45,362; Long-term: $87,776) |
Liquidity: As of September 30, 2025, the company held approximately $633.9 million in cash, cash equivalents, and marketable debt securities. Management believes these resources are sufficient to fund operations through at least the next twelve months.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by $3.2 million (18%) in Q3 2025 compared to Q3 2024, and by $39.6 million (69%) for the nine-month period. This was driven primarily by higher royalty revenues from Alexion (Ultomiris) and milestone payments from Incyte (Monjuvi).
- Net Loss Reduction: Net loss attributable to Xencor improved significantly, decreasing from $46.3 million in Q3 2024 to $6.0 million in Q3 2025. This improvement was largely due to a $44.2 million gain on marketable equity securities (primarily Zenas BioPharma) and reduced operating expenses.
- Operating Expenses: Total operating expenses decreased by $4.5 million in Q3 2025 compared to the prior year, driven by lower stock-based compensation and reduced wind-down costs for terminated programs.
- Asset Impairment: The company recorded $1.6 million in asset impairment charges in Q3 2025 related to paused development programs, compared to no impairment in Q3 2024.
Guidance, Outlook, and Risks
- Outlook: Management expects existing cash, marketable securities, and potential milestone payments to fund operating expenses and capital expenditures into 2028. No specific financial guidance was provided for future quarters.
- Clinical Progress:
- XmAb819: Phase 1 data presented in October 2025 showed a 70% disease control rate in renal cell carcinoma.
- XmAb541: Early efficacy data in ovarian and germ cell tumors showed confirmed partial responses.
- XmAb942: Phase 2b study in ulcerative colitis initiated in Q3 2025.
- Plamotamab: Phase 1b study in rheumatoid arthritis initiated in Q3 2025.
- Material Weaknesses in Internal Controls: The company disclosed that disclosure controls and procedures were not effective due to material weaknesses related to the accounting treatment of proceeds from the sale of future royalties and the evaluation of tax legislation. These weaknesses led to restatements of prior financial statements. Remediation plans are underway.
- Legal Proceedings: Merus N.V. filed a patent infringement lawsuit in August 2024. Xencor's motion to dismiss was granted in October 2025, but Merus has until November 11, 2025, to file an amended complaint. An Inter Partes Review (IPR) was instituted by the PTAB in September 2025.
- Government Shutdown Risk: The filing notes a U.S. government shutdown beginning October 1, 2025, which may delay FDA reviews and SEC filings, potentially impacting capital access and regulatory timelines.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of remediation for the material weaknesses in internal controls over financial reporting, specifically regarding royalty sale accounting and tax legislation evaluation.
- Revenue Sustainability: Assess the sustainability of revenue growth, noting that a significant portion ($18.7M in Q3) is non-cash royalty revenue from Alexion, subject to the Ultomiris Royalty Sale Agreement with OMERS.
- Equity Valuation Volatility: Review the impact of the $44.2 million unrealized gain on marketable equity securities (Zenas BioPharma) on the net loss; this is a non-cash item that may fluctuate significantly.
- Litigation Status: Monitor the outcome of the Merus N.V. patent litigation and the PTAB inter partes review, as an adverse ruling could impact the company's core technology platform.
- Cash Burn Rate: Confirm the runway calculation given the $83.4 million cash used in operating activities for the nine months ended September 30, 2025.